Lexeo Therapeutics Statistics
Total Valuation
LXEO has a market cap or net worth of $122.16 million. The enterprise value is $10.57 million.
Important Dates
The next estimated earnings date is Thursday, May 8, 2025, before market open.
| Earnings Date | May 8, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
LXEO has 33.20 million shares outstanding. The number of shares has increased by 493.67% in one year.
| Current Share Class | 33.20M |
| Shares Outstanding | 33.20M |
| Shares Change (YoY) | +493.67% |
| Shares Change (QoQ) | +0.04% |
| Owned by Insiders (%) | 4.52% |
| Owned by Institutions (%) | 79.61% |
| Float | 21.80M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.04 |
| P/TBV Ratio | 1.05 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.52, with a Debt / Equity ratio of 0.08.
| Current Ratio | 5.52 |
| Quick Ratio | 5.32 |
| Debt / Equity | 0.08 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -772.01 |
Financial Efficiency
Return on equity (ROE) is -85.37% and return on invested capital (ROIC) is -52.48%.
| Return on Equity (ROE) | -85.37% |
| Return on Assets (ROA) | -46.11% |
| Return on Invested Capital (ROIC) | -52.48% |
| Return on Capital Employed (ROCE) | -85.23% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.37M |
| Employee Count | 72 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -70.56% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -70.56% |
| 50-Day Moving Average | 3.12 |
| 200-Day Moving Average | 7.44 |
| Relative Strength Index (RSI) | 59.45 |
| Average Volume (20 Days) | 1,070,726 |
Short Selling Information
The latest short interest is 2.94 million, so 8.85% of the outstanding shares have been sold short.
| Short Interest | 2.94M |
| Short Previous Month | 2.58M |
| Short % of Shares Out | 8.85% |
| Short % of Float | 13.49% |
| Short Ratio (days to cover) | 2.25 |
Income Statement
| Revenue | n/a |
| Gross Profit | -74.09M |
| Operating Income | -105.77M |
| Pretax Income | -69.42M |
| Net Income | -98.33M |
| EBITDA | -105.14M |
| EBIT | -105.77M |
| Earnings Per Share (EPS) | -$3.09 |
Full Income StatementBalance Sheet
The company has $121.52 million in cash and $9.92 million in debt, giving a net cash position of $111.59 million or $3.36 per share.
| Cash & Cash Equivalents | 121.52M |
| Total Debt | 9.92M |
| Net Cash | 111.59M |
| Net Cash Per Share | $3.36 |
| Equity (Book Value) | 116.84M |
| Book Value Per Share | 3.53 |
| Working Capital | 103.28M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$81.15 million and capital expenditures -$481,000, giving a free cash flow of -$81.63 million.
| Operating Cash Flow | -81.15M |
| Capital Expenditures | -481,000 |
| Free Cash Flow | -81.63M |
| FCF Per Share | -$2.46 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |